Goldman Sachs keeps a Buy rating with a A$309 price target on CSL, which is being added to the firm’s new “APAC Conviction List – Directors’ Cut.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CSLLY:
- CSL’s and Arcturus Therapeutics’ mRNA vaccine for COVID approved in Japan
- CSL upgraded to Buy from Neutral at Goldman Sachs
Questions or Comments about the article? Write to editor@tipranks.com